Vaxart, Inc. splits its revenue into 3 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Government Contract at $7.5 million, 71% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
181
|
11
|
27
|
39
|
104
|
72
|
40
|
21
|
15
|
| Government Contract |
—
|
8
-89.6%
share 71.0%
|
24
-38.9%
share 89.2%
|
36
+88.5%
share 92.7%
|
93
+675.3%
share 89.3%
|
72
share 100.0%
|
40
share 100.0%
|
19
share 92.4%
|
12
share 79.1%
|
| Collaboration Revenue |
—
|
3
share 27.5%
|
3
share 10.7%
|
3
share 7.2%
|
—
|
—
|
—
|
—
|
—
|
| Non Cash Royalty Revenue |
—
|
0
share 1.5%
|
0
share 0.0%
|
0
-97.3%
share 0.1%
|
0
-89.0%
share 0.3%
|
—
|
—
|
2
share 7.6%
|
3
share 20.9%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VXRT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 72444
- Former names
- Aviragen Therapeutics, Inc. (until Feb 15, 2018); Biota Pharmaceuticals, Inc. (until Apr 13, 2016); NABI BIOPHARMACEUTICALS (until Nov 8, 2012); NABI BIOPHARMACEUTICALS (until Jun 29, 2010); NABI /DE/ (until Feb 14, 2002)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.